Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5

Sonata Šaulytė Trakymienė*, Marina Economou, Gili Kenet, Andrea Landorph, Chunduo Shen, Susan Kearney

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: N8-GP (turoctocog alfa pegol; Esperoct®, Novo Nordisk A/S, Bagsvaerd, Denmark) is a glycoPEGylated, extended half-life human recombinant factor VIII (FVIII). Objective: Here, we report end-of-trial safety and efficacy results from the completed N8-GP pathfinder5 trial. Methods: pathfinder5 (NCT01731600) was a multi-national, open-label, single-arm, non-randomized, non-controlled trial in previously treated male patients aged <12 years old with severe hemophilia A that comprised a main and an extension phase. During the main phase, patients received twice-weekly N8-GP 60 IU/kg for 50 exposure days (~26 weeks). During the extension phase, patients received the same regimen until the end of trial (first patient in main phase, 20 February 2013; trial end, 28 September 2018). Results: Sixty-eight patients were exposed to N8-GP for a median time of ~4.9 years on regimen. Of the 63 patients who started in the extension phase, 62 completed the trial. No FVIII inhibitors (≥0.6 BU) or other safety concerns were detected. The overall estimated annualized bleeding rate was 1.08 (median 0.81), and nearly 20% of patients had no bleeds during the entire trial. The proportion of patients with no annual bleeds increased with time, with 56% of patients experiencing no bleeds and 86% experiencing no spontaneous bleeds during the fourth year of exposure. All baseline target joints of patients who participated in both phases of this trial were resolved in slightly over 2 years. Conclusion: Overall, data from the completed pathfinder5 trial show that long-term (median 4.9 years) N8-GP treatment was efficacious and well tolerated in previously treated pediatric patients with severe hemophilia A.

Original languageEnglish
Pages (from-to)15-25
Number of pages11
JournalJournal of Thrombosis and Haemostasis
Volume18
Issue numberS1
DOIs
StatePublished - 1 Sep 2020

Funding

FundersFunder number
Physicians World Europe GmbH
Novo Nordisk

    Keywords

    • child
    • clinical trial
    • factor VIII
    • hemophilia A
    • turoctocog alfa pegol

    Fingerprint

    Dive into the research topics of 'Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5'. Together they form a unique fingerprint.

    Cite this